Skip to main content
. 2020 Jan 6;15:3. doi: 10.1186/s13023-019-1280-5

Table 4.

Delay to initiate treatment with EMA-approved OMPs for HMDs following prescription in the MetabERN participating countries

graphic file with name 13023_2019_1280_Tab4_HTML.jpg